New Treatment Guidelines for Candidiasis – A Major Document to Study

In a much-quoted analysis, Lee found that most IDSA Guidelines were supported only by Level III quality data, the lowest category of evidence-based support[1]. The article concludes that more well-designed trials were needed, and clinical judgement should ultimately guide patient Continue reading New Treatment Guidelines for Candidiasis – A Major Document to Study

QIDP Antibiotics – 2015 Year-End Update

Here an updated listing of all QIDP drugs we are aware of as of 12/24/2015. Today just facts and numbers; we will provide an interpretation of the current landscape in upcoming blogs. There are 58 drugs which garnered QIDP status and these Continue reading QIDP Antibiotics – 2015 Year-End Update

Cresemba / Isavuconazole:  Not Just Another Azole

It is amazing how modifications to the azole structure have produced ever more potent, ever more useful antifungals.  Ketoconazole had limited usability because of its many side effects related to off-target sterol synthesis inhibition, solubility (or lack thereof) and erratic Continue reading Cresemba / Isavuconazole:  Not Just Another Azole

Nikkomycins Are Finally Getting Some Respect

Besides azoles, candins and the polyene class of antifungals there is not much to select from when it comes to systemic fungal infections.  Until the recent arrival of voriconazole and posaconazole, infections caused by molds always required amphotericin B to Continue reading Nikkomycins Are Finally Getting Some Respect

QT Prolongation with Azithromycin and Levofloxacin

Several antibiotic classes are associated with QTc prolongation: macrolides, quinolones, the antimalarials that share the quinine structure, and many azole antifungals.  FDA warned about the proarrhythmic effects of azithromycin in 2013 [i] but it is a recent publication by Rao Continue reading QT Prolongation with Azithromycin and Levofloxacin